RVL Pharmaceuticals in discussions to acquire counterparty in all-stock deal

RVL Pharmaceuticals announced that, as authorized by the Board of Directors, the Company has been considering certain strategic alternatives. These include discussions to acquire a specific potential counterparty in an all stock strategic transaction and discussions with potential financing sources regarding incremental funding for the combined company in the event such a transaction is consummated. This strategic transaction, if consummated, would result in a more diversified aesthetics company with meaningful revenue and synergies. In addition, the Company is in business development discussions with other parties to further enhance the business on a go-forward basis. There is no certainty that the Company will enter into a strategic transaction or that any financing will be consummated. Further announcements will be made as and when appropriate.